Mold-Tek Packaging Reports Financial Results for FY26; Highlights Strong Growth in Pharma Sector

Mold-Tek Packaging Reports Financial Results for FY26; Highlights Strong Growth in Pharma Sector​

Mold-Tek Packaging Limited announced its financial results for the quarter and year ended March 31, 2026, citing strong operational performance and steady revenue growth across its key business segments. The company's growth narrative was driven by standout performance in the pharmaceutical sector and strategic capacity enhancements.

During the financial year 2025-26, the company reported a revenue increase of 13.48% year-on-year, with sales volumes growing by 11.39%.

Financial Performance Overview​

The company provided detailed financial figures for both the full fiscal year and the fourth quarter (Q4) of FY26.

The financial results for the fiscal year 2025-26 are summarized below:


For the fourth quarter of FY26, Mold-Tek Packaging Limited reported significant increases across major financial metrics:


The company also declared and paid an Interim Equity Dividend for the Financial Year 2025-26 at a rate of 40%, amounting to Rs. 2.00 per equity share on a face value of Rs. 5.00 per equity share.

Operational and Segment Highlights​

Speaking on the performance, Mr. J. Lakshmana Rao, Chairman and Managing Director, stated that the consolidation of five units in Hyderabad into two units, coupled with better capacity utilization, is expected to boost the company’s performance starting from FY 2026-27 onwards.

Segment performance highlighted the exceptional growth in the pharmaceutical sector. The Pharma Packs segment demonstrated a volume growth of 208.96% and achieved a projected turnover of Rs. 35 Crores. The FMCG Packs segment maintained robust growth with an 18.04% volume increase, while the Q-Packs segment registered a 25.82% growth. The Paint Packs segment also reported a healthy volume growth of 14.41% during FY 2025-26. Conversely, the Lubes Packs segment experienced a volume decline of 12.99%.

Capacity Expansion and Strategic Moves​

Mold-Tek Packaging continues to expand its infrastructure to meet rising demand. Over the course of the year, the company added 28 CRC assembling machines and one IBM machine. Additionally, the launch of Effervescent tubes, which was noted as a first-time introduction in India for 85,99,120,144 mm sizes, marks a product innovation milestone.

On the capacity front, the company significantly increased production capacity at Panipat in Haryana, Satara in Maharashtra, and Cheyyar in Tamil Nadu to effectively manage the increased demand from the Aditya Birla Group.

Furthermore, the company completed the 50% construction of a new factory building at Mahad to cater to Grasim Industries Ltd. Supplies from this facility are slated to begin in Q2 of FY27.

In a strategic consolidation effort, Moldtek optimized its manufacturing presence in Hyderabad by discontinuing operations at Unit-6, Unit-2, Unit-4, and the warehouse at Hosur. All manufacturing activities were consolidated into the larger, more efficient facilities located at Unit-1 and Unit-10. These improvements are anticipated to generate operational synergies and financial benefits fully realized from FY 2026-27.

The company also strengthened its printing infrastructure by adding new offset printing machinery to address existing production bottlenecks, with plans to add one more machine by August 2026.

The firm successfully secured new orders during the period from reputed companies, including Aadharsh Chemicals, Coromandel Internal, Anatha Food, Even Hub, Shansi Unit RSOL (from the food industry), and DifGen Pharmaceuticals Pvt Ltd (from the pharma sector).

Mold-Tek Packaging expressed confidence in crossing a turnover of Rs. 1,000 crores during FY 2026-27, expecting continued growth supported by the aforementioned capacity expansions and market contributions.

MOLDTKPAC Stock Price Movement​

Shares of Mold-Tek Packaging Limited today slipped by 0.80% to settle at ₹584.5. The stock traded on a robust volume of 674,833 shares, signaling notable interest in the equity.